United Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on the stock and has a $447.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Hold rating due to a combination of factors influencing United Therapeutics’ current market position and future outlook. Despite the company’s recent third-quarter performance missing expectations, the stock has seen a notable increase following management’s optimistic commentary about potential partnerships for Tyvaso, particularly in regions outside the United States. This potential for collaboration could open new revenue streams, although no active discussions are currently underway.
Additionally, United Therapeutics has adjusted its long-term revenue goals, now aiming for a $4 billion annualized revenue run-rate by 2027, which is a delay from previous projections. While the company’s Tyvaso product shows promise, with sales slightly exceeding some estimates and a new cartridge launch planned, the competitive landscape remains a challenge. The balance of risks and rewards, especially with upcoming data from ongoing trials, supports the decision to maintain a Hold rating as the company navigates these dynamics.
In another report released today, Wells Fargo also maintained a Hold rating on the stock with a $423.00 price target.
Based on the recent corporate insider activity of 188 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.